https://finance.yahoo.com/news/biotech-stock-roundup-amgn-resubmits-120812639.html
It should sell about $1.50 if ever approved. That will make up for the Repatha shortfall bigtime.
It should sell about $1.50 if ever approved. That will make up for the Repatha shortfall bigtime.